Cover Image
市場調查報告書

唐氏症 : 開發中產品分析

Down Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 251580
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
唐氏症 : 開發中產品分析 Down Syndrome - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 65 Pages
簡介

唐氏症是會造成一輩子認知障礙、發育遲緩等問題的遺傳性疾病。病症從輕微到嚴重各有不同。

本報告提供唐氏症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

唐氏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AC Immune SA
  • Aelis Farma SAS
  • Cortice Biosciences, Inc.
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • NeuroNascent, Inc.
  • Transition Therapeutics Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8974IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Pipeline Review, H1 2017, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Down Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Down Syndrome - Overview
  • Down Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Down Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Down Syndrome - Companies Involved in Therapeutics Development
    • AC Immune SA
    • Aelis Farma SAS
    • Cortice Biosciences Inc
    • Eisai Co Ltd
    • ManRos Therapeutics
    • NeuroNascent Inc
    • OPKO Health Inc
  • Down Syndrome - Drug Profiles
    • ACI-24 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALZ-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APH-1104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • donepezil hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dosmir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELND-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • minocycline hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-362 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentylenetetrazol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome, Dyskeratosis Congenita and Edwards Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xamoterol fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Down Syndrome - Discontinued Products
  • Down Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome
      • Aug 31, 2015: New Down syndrome therapy discovered
      • Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics
      • Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome
      • Apr 07, 2014: Transition Therapeutics Announces Development Update
      • Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome
      • Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Down Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Down Syndrome - Pipeline by AC Immune SA, H1 2017
  • Down Syndrome - Pipeline by Aelis Farma SAS, H1 2017
  • Down Syndrome - Pipeline by Cortice Biosciences Inc, H1 2017
  • Down Syndrome - Pipeline by Eisai Co Ltd, H1 2017
  • Down Syndrome - Pipeline by ManRos Therapeutics, H1 2017
  • Down Syndrome - Pipeline by NeuroNascent Inc, H1 2017
  • Down Syndrome - Pipeline by OPKO Health Inc, H1 2017
  • Down Syndrome - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Down Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top